{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:28:01Z","timestamp":1791908881065,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07408-z","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:46:36Z","timestamp":1765536396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Jiacheng","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuda","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changbin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7176","authenticated-orcid":false,"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"7408_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA: A Cancer J For Clinicians"},{"key":"7408_CR2","doi-asserted-by":"crossref","unstructured":"Duma N, Santana-Davila R, Molina JR. Non\u2013small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clinic Proc. Elsevier; 2019;1623\u201340.","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"7408_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","volume":"18","author":"MJ Grant","year":"2021","unstructured":"Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18:625\u201344.","journal-title":"Nat Rev Clin Oncol"},{"key":"7408_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. NEJM Evid. 2018;378:2078\u201392.","journal-title":"NEJM Evid"},{"key":"7408_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer. NEJM Evid. 2018;379:2040\u201351.","journal-title":"NEJM Evid"},{"key":"7408_CR6","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer. NEJM Evid. 2017;376:2415\u201326.","journal-title":"NEJM Evid"},{"key":"7408_CR7","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.21.02885","volume":"41","author":"G de Castro Jr","year":"2023","unstructured":"de Castro Jr G, Kudaba I, Wu Y-L, Lopes G, Kowalski DM, Turna HZ, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non\u2013small-cell lung cancer and programmed death ligand-1 tumor proportion score\u2265 1% in the KEYNOTE-042 study. J Clin Oncol. 2023;41:1986\u201391.","journal-title":"J Clin Oncol"},{"key":"7408_CR8","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. NEJM Evid. 2012;366:2443\u201354.","journal-title":"NEJM Evid"},{"key":"7408_CR9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.","journal-title":"Nature"},{"key":"7408_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u201367.","journal-title":"Nature"},{"key":"7408_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. NEJM Evid. 2015;373:123\u201335.","journal-title":"NEJM Evid"},{"key":"7408_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. NEJM Evid. 2013;369:122\u201333.","journal-title":"NEJM Evid"},{"key":"7408_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. NEJM Evid. 2015;372:320\u201330.","journal-title":"NEJM Evid"},{"key":"7408_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257\u201365.","journal-title":"The Lancet Oncol"},{"key":"7408_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33:843\u201352. e844.","journal-title":"Cancer Cell"},{"key":"7408_CR16","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.18.01042","volume":"37","author":"N Ready","year":"2019","unstructured":"Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, et al. First-line nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol. 2019;37:992\u20131000.","journal-title":"J Clin Oncol"},{"key":"7408_CR17","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer. NEJM Evid. 2019;381:2020\u201331.","journal-title":"NEJM Evid"},{"key":"7408_CR18","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti\u2013PD-1 therapy. Clin Cancer Res. 2014;20:5064\u201374.","journal-title":"Clin Cancer Res"},{"key":"7408_CR19","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41467-018-05032-8","volume":"9","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Choi J, Mani N, Sanmamed M, Datar I, Sowell R, et al. A dormant til phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun. 2018;9:3196.","journal-title":"Nat Commun"},{"key":"7408_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jtho.2023.03.012","volume":"18","author":"D Sun","year":"2023","unstructured":"Sun D, Liu J, Zhou H, Shi M, Sun J, Zhao S, et al. Classification of tumor immune microenvironment according to programmed death-ligand 1 expression and immune infiltration predicts response to immunotherapy plus chemotherapy in advanced patients with NSCLC. J Thorac Oncol. 2023;18:869\u201381.","journal-title":"J Thorac Oncol"},{"key":"7408_CR21","doi-asserted-by":"publisher","first-page":"abe6474","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng L, Qin S, Si W, Wang A, Xing B, Gao R, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374:abe6474.","journal-title":"Science"},{"key":"7408_CR22","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","volume":"17","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011;17:6287\u201397.","journal-title":"Clin Cancer Res"},{"key":"7408_CR23","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","volume":"50","author":"R Zilionis","year":"2019","unstructured":"Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50:1317\u201334. e1310.","journal-title":"Immunity"},{"key":"7408_CR24","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.4049\/jimmunol.165.7.3797","volume":"165","author":"M Nouri-Shirazi","year":"2000","unstructured":"Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000;165:3797\u2013803.","journal-title":"The J Immunol"},{"key":"7408_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science. 2015;348:124\u201328.","journal-title":"Science"},{"key":"7408_CR26","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","volume":"25","author":"I Datar","year":"2019","unstructured":"Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non\u2013small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res. 2019;25:4663\u201373.","journal-title":"Clin Cancer Res"},{"key":"7408_CR27","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","volume":"26","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, et al. Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res. 2020;26:970\u201377.","journal-title":"Clin Cancer Res"},{"key":"7408_CR28","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","volume":"16","author":"Y Yang","year":"2021","unstructured":"Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, et al. Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. J Thorac Oncol. 2021;16:2109\u201320.","journal-title":"J Thorac Oncol"},{"key":"7408_CR29","doi-asserted-by":"crossref","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365.","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"7408_CR30","unstructured":"Andrews S. FastQC: a quality control tool for high throughput sequence data. (No Title) 2010."},{"key":"7408_CR31","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114\u201320.","journal-title":"Bioinformatics"},{"key":"7408_CR32","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37:907\u201315.","journal-title":"Nat Biotechnol"},{"key":"7408_CR33","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923\u201330.","journal-title":"Bioinformatics"},{"key":"7408_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics J Intgr Biol. 2012;16:284\u201387.","journal-title":"Omics: A J Intgr Biol"},{"key":"7408_CR35","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci, India, Sect B Biol Sci"},{"key":"7408_CR36","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739\u201340.","journal-title":"Bioinformatics"},{"key":"7408_CR37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39:845\u201365. e847.","journal-title":"Cancer Cell"},{"key":"7408_CR38","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782\u201395.","journal-title":"Immunity"},{"key":"7408_CR39","doi-asserted-by":"crossref","unstructured":"Franz\u00e9n O, Gan LM, Bj\u00f6rkegren JLM. PanglaoDB: a web server for exploration of mouse and human single-cell rna sequencing data. Database (oxford). 2019;2019.","DOI":"10.1093\/database\/baz046"},{"key":"7408_CR40","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang F, Li J, Qi L, Liu D, Bo Y, Qin S, et al. A pan-cancer single-cell panorama of human natural killer cells. Cell. 2023;186:4235\u201351. e4220.","journal-title":"Cell"},{"key":"7408_CR41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564:268\u201372.","journal-title":"Nature"},{"key":"7408_CR42","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184:792\u2013809. e723.","journal-title":"Cell"},{"key":"7408_CR43","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.annonc.2022.08.084","volume":"33","author":"Y Bareche","year":"2022","unstructured":"Bareche Y, Kelly D, Abbas-Aghababazadeh F, Nakano M, Esfahani PN, Tkachuk D, et al. Leveraging big data of immune checkpoint blockade response identifies novel potential targets. Ann Oncol. 2022;33:1304\u201317.","journal-title":"Ann Oncol"},{"key":"7408_CR44","doi-asserted-by":"crossref","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-source package for R and S+ to analyze and compare roc curves. BMC Bioinformatics. 2011;12:1\u20138.","DOI":"10.1186\/1471-2105-12-77"},{"key":"7408_CR45","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cell.2018.03.026","volume":"173","author":"SA Shukla","year":"2018","unstructured":"Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, et al. Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade. Cell. 2018;173:624\u201333. e628.","journal-title":"Cell"},{"key":"7408_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","volume":"40","author":"NS Patil","year":"2022","unstructured":"Patil NS, Nabet BY, M\u00fcller S, Koeppen H, Zou W, Giltnane J, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 2022;40:289\u2013300. e284.","journal-title":"Cancer Cell"},{"key":"7408_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41588-022-01243-4","volume":"55","author":"E Madissoon","year":"2023","unstructured":"Madissoon E, Oliver AJ, Kleshchevnikov V, Wilbrey-Clark A, Polanski K, Richoz N, et al. A spatially resolved atlas of the human lung characterizes a gland-associated immune niche. Nat Genet. 2023;55:66\u201377.","journal-title":"Nat Genet"},{"key":"7408_CR48","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer\u2013dendritic cell axis defines checkpoint therapy\u2013responsive tumor microenvironments. Nat Med. 2018;24:1178\u201391.","journal-title":"Nat Med"},{"key":"7408_CR49","doi-asserted-by":"crossref","unstructured":"Huang J, You G, Chen Q, Lin Y, Liang Y, Lin C, et al. Immunosuppressive microenvironment in H3K27 mutant pediatric diffuse midline glioma: single-cell and bioinformatics insights on CD8A, IL7R, and ICAM1. Curr Med Chem. 2024.","DOI":"10.2174\/0109298673280120240108045926"},{"key":"7408_CR50","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3349\/ymj.2024.0062","volume":"65","author":"Y Kim","year":"2024","unstructured":"Kim Y, Hwang JY, Na K, Kim DK, Lee S, Kang S-S, et al. Mutation-driven immune microenvironments in non-small cell lung cancer: unrevealing patterns through cluster analysis. Yonsei Med J. 2024;65:683.","journal-title":"Yonsei Med J"},{"key":"7408_CR51","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1161\/ATVBAHA.123.318974","volume":"43","author":"J Tan","year":"2023","unstructured":"Tan J, Liang Y, Yang Z, He Q, Tong J, Deng Y, et al. Single-cell transcriptomics reveals crucial cell subsets and functional heterogeneity associated with carotid atherosclerosis and cerebrovascular events. Arterioscler Thromb Vasc Biol. 2023;43:2312\u201332.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7408_CR52","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.chest.2020.01.048","volume":"158","author":"R Zhang","year":"2020","unstructured":"Zhang R, Chen C, Dong X, Shen S, Lai L, He J, et al. Independent validation of early-stage non-small cell lung cancer prognostic scores incorporating epigenetic and transcriptional biomarkers with gene-gene interactions and main effects. Chest. 2020;158:808\u201319.","journal-title":"Chest"},{"key":"7408_CR53","doi-asserted-by":"crossref","unstructured":"Li X, Kolling FW, Aridgides D, Mellinger D, Ashare A, Jakubzick CV. ScRNA-seq expression of IFI27 and APOC2 identifies four alveolar macrophage superclusters in healthy BALF. Life Sci Alliance. 2022;5.","DOI":"10.1101\/2022.01.30.478325"},{"key":"7408_CR54","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","volume":"185","author":"RN Ramos","year":"2022","unstructured":"Ramos RN, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, N\u00fa\u00f1ez NG, et al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell. 2022;185:1189\u2013207. e1125.","journal-title":"Cell"},{"key":"7408_CR55","doi-asserted-by":"publisher","first-page":"1040668","DOI":"10.3389\/fimmu.2022.1040668","volume":"13","author":"W Chang","year":"2022","unstructured":"Chang W, Li H, Zhong L, Zhu T, Chang Z, Ou W, et al. Development of a copper metabolism-related gene signature in lung adenocarcinoma. Front Immunol. 2022;13:1040668.","journal-title":"Front Immunol"},{"key":"7408_CR56","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.3390\/cimb45100536","volume":"45","author":"T Liu","year":"2023","unstructured":"Liu T, Wei J. Validation of a novel cuproptosis\u2013related prognostic gene marker and differential expression associated with lung adenocarcinoma. Curr Issues Mol Biol. 2023;45:8502\u201318.","journal-title":"Curr Issues Mol Biol"},{"key":"7408_CR57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.31083\/j.fbl2903123","volume":"29","author":"R Zhu","year":"2024","unstructured":"Zhu R, Wang X, Sun F, Zhu L, Guo W. Exploring the role of dna methylation located in cuproptosis-related genes: implications for prognosis and immune landscape in hepatocellular carcinoma. Front Biosci-Landmark. 2024;29:123.","journal-title":"Front Biosci-Landmark"},{"key":"7408_CR58","doi-asserted-by":"publisher","first-page":"e2311630121","DOI":"10.1073\/pnas.2311630121","volume":"121","author":"J Lu","year":"2024","unstructured":"Lu J, Liu X, Li X, Li H, Shi L, Xia X, et al. Copper regulates the host innate immune response against bacterial infection via activation of ALPK1 kinase. Proc Natl Acad Sci. 2024;121:e2311630121.","journal-title":"Proc Natl Acad Sci, India, Sect B Biol Sci"},{"key":"7408_CR59","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa H, Barber GN. Sting is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455:674\u201378.","journal-title":"Nature"},{"key":"7408_CR60","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/ncomms2608","volume":"4","author":"Z Zhong","year":"2013","unstructured":"Zhong Z, Zhai Y, Liang S, Mori Y, Han R, Sutterwala FS, et al. TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun. 2013;4:1611.","journal-title":"Nat Commun"},{"key":"7408_CR61","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic dna sensor that activates the type I interferon pathway. Science. 2013;339:786\u201391.","journal-title":"Science"},{"key":"7408_CR62","doi-asserted-by":"crossref","unstructured":"Bose T, Cie\u015blar-Pobuda A, Wiechec E. Role of ion channels in regulating Ca2+ homeostasis during the interplay between immune and cancer cells. Cell Death Dis. 2015;6:e1648.","DOI":"10.1038\/cddis.2015.23"},{"key":"7408_CR63","first-page":"5509","volume":"8","author":"C Su","year":"2015","unstructured":"Su C, Xu Y, Li X, Ren S, Zhao C, Hou L, et al. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8:5509.","journal-title":"Int J Clin And Exp Pathol"},{"key":"7408_CR64","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/ijc.25777","volume":"129","author":"E Schultz-Thater","year":"2011","unstructured":"Schultz-Thater E, Piscuoglio S, Iezzi G, Le Magnen C, Zajac P, Carafa V, et al. MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int J Cancer. 2011;129:1137\u201348.","journal-title":"Int J Cancer"},{"key":"7408_CR65","doi-asserted-by":"publisher","first-page":"e20365","DOI":"10.1371\/journal.pone.0020365","volume":"6","author":"Y Katsura","year":"2011","unstructured":"Katsura Y, Satta Y. Evolutionary history of the cancer immunity antigen MAGE gene family. PLoS One. 2011;6:e20365.","journal-title":"PLoS One"},{"key":"7408_CR66","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ccell.2016.05.016","volume":"30","author":"F Pietrocola","year":"2016","unstructured":"Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016;30:147\u201360.","journal-title":"Cancer Cell"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07408-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:03:38Z","timestamp":1765541018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07408-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7408"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07408-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We the undersigned declare that this manuscript entitled \u201cTumor Immune Microenvironment Score Predicts Efficacy of Immune Checkpoint Inhibitors-Based Regimens in Advanced Non-Small Cell Lung Cancer\u201d is original, has not been published before and is not currently being considered for publication elsewhere. We would like to draw the attention of the Editor to the following publications of one or more of us that refer to aspects of the manuscript presently being submitted. Where relevant copies of such publications are attached. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.We understand that the Corresponding Author is the sole contact for the Editorial process. He\/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.W., X.L., P.C., and C.Z. are employed by Amoy Diagnostics. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1391"}}